[1] Jones B, Dale RG, Deehan C, et al. The role of biologically effective dose(BED) in clinical oncology[J]. Clin Oncol(R Coll Radiol), 2001, 13(2):71-81. DOI:10.1053/clon.2001.9221.
[2] Fowler JF. 21 years of biologically effective dose[J]. Br J Radiol, 2010, 83(991):554-568. DOI:10.1259/bjr/31372149.
[3] Mouttet-Audouard R, Lacornerie T, Tresch E, et al. What is the normal tissues morbidity following Helical Intensity Modulated Radiation Treatment for cervical cancer?[J]. Radiother Oncol, 2015, 115(3):386-391. DOI:10.1016/j.radonc.2015.02.010.
[4] Hopewell JW, Millar WT, Lindquist C, et al. Application of the concept of biologically effective dose (BED) to patients with Vestibular Schwannomas treated by radiosurgery[J]. J Radiosurg SBRT, 2013, 2(4):257-271.
[5] Su SF, Huang Y, Xiao WW, et al. Clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3):312-316. DOI:10.1016/j.radonc.2012.06.012.
[6] Lee SH, Lee KC, Choi J, et al. Clinical applicability of biologically effectivedose calculation for spinal cord in fractionatedspine stereotactic body radiation therapy[J]. Radiol Oncol, 2015, 49(2):185-191. DOI:10.1515/raon-2015-0008.
[7] Wambersie A, Menzel HG, Gahbauer RA, et al. Biological weighting of absorbed dose in radiation therapy[J]. Radiat Prot Dosimetry, 2002, 99(1/4):445-452.
[8] Iwata H, Matsufuji N, Toshito T, et al. Compatibility of the repairable-conditionally repairable, multi-target and linear-quadratic models in converting hypofractionated radiation doses to single doses[J]. J Radiat Res, 2013, 54(2):367-373. DOI:10.1093/jrr/rrs089.
[9] Jin JY, Huang YM, Brown SL, et al. Radiation dose-fractionation effects in spinal cord:comparison of animal and human data[J]. J Radiat Oncol, 2015, 4(3):225-233. DOI:10.1007/s13566-015-0212-9.
[10] Deloch L, Derer A, Hartmann J, et al. Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation[J]. Front Oncol, 2016, 6:141. DOI:10.3389/fonc.2016.00141.
[11]

李玉, 徐慧军.现代肿瘤放射物理学[M].北京:中国原子能出版社, 2015:526-530.

Li Y, Xu HJ. Modern radiophysicson tumor[M]. Beijing:China Atomic Energy Press, 2015:526-530.
[12] Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma:a prospective randomized study[J]. Int J Radiat Oncol Biol Phys, 2013, 87(3):542-548. DOI:10.1016/j.ijrobp.2013.06.2059.
[13]

Co J, Mejia MB, Dizon JM. Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta-analysis and a systematic review of the literature[J]. Head Neck, 2016, 38 Suppl 1: E2130S-2142. DOI: 10.1002/hed.23977.
[14] Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3):286-293. DOI:10.1016/j.radonc.2012.08.013.
[15] Zhang MX, Li J, Shen GP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy:A 10-year experience with a large cohort and long follow-up[J]. Eur J Cancer, 2015, 51(17):2587-2595. DOI:10.1016/j.ejca. 2015.08.006.
[16]

Zhou GQ, Yu XL, Chen M, et al. Radiation-induced temporal lobe injury for nasopharyngeal carcinoma: a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy[J/OL]. PLoS One, 2013, 8(7): e67488[2018-02-05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707870/pdf/pone.0067488.pdf. DOI: 10.1371/journal.pone.0067488.
[17] Dolezel M, Odrazka K, Zouhar M, et al. Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer[J]. Strahlenther Onkol, 2015, 191(4):338-346. DOI:10.1007/s00066-014-0806-y.
[18]

殷蔚伯, 余子豪, 徐国镇, 等.肿瘤放射治疗学[M]. 4版.北京:中国协和医科大学出版社, 2008:276.

Yin WB, Yu ZH, Xu GZ, et al. Radiation oncology[M]. 4th ed. Beijing:China Union Medical University Press, 2008:276.
[19] Chadwick HK, Leenhouts HP. A molecular therapy of cell survival[J]. Physic Med Biol, 1973, 18:78-87.  doi: 10.1088/0031-9155/18/1/007
[20] Sanpaolo P, Barbieri V, Genovesi D. Biologically effective dose and definitive radiation treatment for localized prostate cancer:treatment gaps do affect the risk of biochemical failure[J]. Strahlenther Onkol, 2014, 190(8):732-738. DOI:10.1007/s00066-014-0642-0.
[21] Jin JY, Huang Y, Brown SL, et al. Radiation dose-fractionation effects in spinal cord:comparison of animal and human data[J]. J Radiat Oncol, 2015, 4(3):225-233. DOI:10.1007/s13566-015-0212-9.
[22] Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses[J]. Int J Radiat Oncol Biol Phys, 1982, 8(11):1981-1997.  doi: 10.1016/0360-3016(82)90459-X
[23] Maciejewski B, Taylor JM, Withers HR. Alpha/beta value and the importance of size of dose per fraction for late complications in the supraglottic larynx[J]. Radiother Oncol, 1986, 7(4):323-326.  doi: 10.1016/S0167-8140(86)80061-5
[24] Brenner DJ. Fractionation and late rectal toxicity[J]. Int J Radiat Oncol Biol Phys, 2004, 60(4):1013-1015. DOI:10.1016/j.ijrobp.2004.04.014.
[25] Miralbell R, Robert SA, Zubizarreta E, et al. Dose-fraction sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets:α/β=1.4(0.9-2.2) Gy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):e17-24. DOI:10.1016/j.ijrobp.2010.10.075.
[26] Turesson I, Notter G. The influence of fraction size in radiotherapy on the late normal tissue reaction -Ⅰ:Comparison of the effects of daily and once-a-week fractionation on human skin[J]. Int J Radiat Oncol Biol Phys, 1984, 10(5):593-598.  doi: 10.1016/0360-3016(84)90289-X
[27] Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation:an analysis of the radiation therapy oncology group[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):425-434. DOI:10.1016/j.ijrobp.2010.09.004.
[28] Xia B, Chen GY, Cai XW, et al. The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer[J]. Radiat Oncol, 2011, 6:50. DOI:10.1186/1748-717X-6-50.